[AZN] AstraZeneca: Q3 2026 Earnings Preview, Can Oncology Offset Farxiga Generics?

AstraZeneca, a UK-based global drugmaker focused on patented oncology, biopharmaceutical and rare disease medicines, plans to publish its AstraZeneca Q3 2026 earnings, covering the third quarter of 2026, ending September 30, 2026, together with nine-month results, on 2026-10-30[1]. In the latest reported period, the second quarter of 2026, Total Revenue was $15.38 billion, up 5% at constant exchange rates (CER); Oncology revenue was $7.33 billion, up 15%, BioPharmaceuticals fell 7% and China revenue fell 13%[2]. Core gross margin was 84%, core operating profit was $5.16 billion for a 34% margin, and core EPS was $2.63, up 18%[3]. On July 27 the company reaffirmed its FY2026 guidance for Total Revenue growth of a mid-to-high single-digit percentage and core EPS growth of a low double-digit percentage at CER, with a core tax rate of 18%-22%, and it does not give quarterly guidance[4]. Seven analysts compiled by Drillr put third-quarter revenue consensus at $16.06 billion (range $15.91 billion to $16.29 billion), above the $15.38 billion actually reported for the second quarter; the EPS consensus that matches the company's core EPS basis is $2.62, but only two analysts contribute and the range runs from $1.59 to $3.14, so it carries limited weight[5].

Three things matter most in these results. First, can Oncology hold growth above 13% through new indications for Imfinzi (up 27% in the second quarter) and Enhertu (up 31%) while Tagrisso grows only 6%? Oncology was 48% of second-quarter revenue and is the company's main offset to declining older medicines[6]. Second, US Farxiga revenue fell to $219 million in the second quarter after multiple generics launched, and the third quarter is the first full quarter with generics on the market, so the size of that decline will show whether the low end of full-year revenue guidance is under pressure[7][8]. Third, management has already flagged a seasonally lower gross margin and higher finance costs in the second half, so whether the core operating margin can hold around 33% will decide whether nine-month core EPS growth stays within the low double-digit guidance[9].

Company Background and Business Structure

AstraZeneca is a large pharmaceutical group formed from the merger of the UK's Zeneca and Sweden's Astra, which later filled out its biologics and rare disease businesses through acquisitions. Zeneca was demerged from Imperial Chemical Industries (ICI) in 1993 and merged with Astra in 1999; the group then acquired biologics company MedImmune in 2007 and US rare disease company Alexion in 2021, and in 2026 it terminated its ADR programme and listed all of its ordinary shares directly on the New York Stock Exchange[10]. The company had about 96,100 employees at the end of 2025[11]. Its medium-term ambition is to launch at least 20 new medicines and reach $80 billion in Total Revenue by 2030[12], and in July 2026 management described that target as a risk-adjusted forecast that already allows for trial failures[13]. In October 2025 the company reached an agreement with the US government that lowers the US price of some prescription medicines in exchange for greater pricing clarity and a three-year tariff exemption, and it plans to invest $50 billion in US manufacturing and R&D[14].

AstraZeneca's revenue comes from Product Sales, Alliance Revenue and Collaboration Revenue, and Oncology is its largest therapy area. In 2025 Total Revenue was $58.74 billion: Product Sales of $55.57 billion are sales the company makes itself to wholesalers, hospitals and pharmacies, recognized at net price; Alliance Revenue of $3.07 billion is the gross-profit share or royalty AstraZeneca receives after partners book sales, mainly Enhertu with Daiichi Sankyo, Tezspire with Amgen and Beyfortus with Sanofi; Collaboration Revenue was only $99 million[15]. By therapy area, Oncology generated $25.6 billion (44%), BioPharmaceuticals $23.0 billion (39%), Rare Disease $9.1 billion (16%) and other older medicines about $1.0 billion; by region, the US contributed $25.5 billion (43%), Emerging Markets $15.3 billion (26%), Europe $12.7 billion (22%) and Established Rest of World $5.2 billion (9%)[16]. China is the most important single country within Emerging Markets: its 2025 Product Sales were $6.62 billion, 12% of the company's Product Sales[17].

The business model trades heavy R&D spending for high margins during patent life, and patent expiry is its main structural constraint. Core R&D expense was 23% of revenue in the first half of 2026; the patented medicines it produces are approved by regulators, promoted by the company's own sales teams to oncology, respiratory and rare disease specialists, and supplied through wholesalers and hospitals[18]. US revenue is shaped by commercial insurance, Medicare discounts and gross-to-net adjustments, while China revenue depends on national reimbursement (NRDL) negotiations and volume-based procurement (VBP), which set both price and volume. Manufacturing costs are low, and core gross margin was 84% in the second quarter[3], but profit-sharing products such as Lynparza, Enhertu, Datroway and Tezspire book the share paid to partners in cost of sales, which lowers gross margin; price cuts on medicines past exclusivity and pricing changes under the US government agreement also weigh on it[19]. Once a patent expires and generics or biosimilars enter, the originator's price and volume usually fall sharply within a few quarters.

Financial History and Current Position

AstraZeneca's annual revenue and profit have grown for three straight years, and reported profit recovered much faster than core profit in 2025. Total Revenue rose from $45.81 billion in 2023 to $54.07 billion in 2024 and $58.74 billion in 2025, up 9% at actual rates and 8% at CER in 2025[15]. Reported operating profit was $13.74 billion in 2025, up 37%, and core operating profit was $18.48 billion, up 9%, for a core operating margin of about 31.5%; reported EPS was $6.60 and core EPS was $9.16, up 12%[15]. Net cash from operating activities was $14.58 billion in 2025, up from $11.86 billion in 2024[20]; capital expenditure on property, plant, equipment and software was $3.27 billion that year, and the company plans to raise such spending by about a third in 2026 and lift its annual dividend to $3.30 per share[21].

Revenue growth slowed from 8% to 5% across the first two quarters of 2026, yet the core margin rose. First-quarter Total Revenue was $15.29 billion, up 8% at CER, core operating profit rose 12%, and core EPS rose 5%, held back by a low tax rate in the prior-year quarter[22]; first-quarter core operating profit was $5.35 billion and core EPS was $2.58[23]. Second-quarter Total Revenue was $15.38 billion, up 5%: Oncology was $7.33 billion, up 15%; Rare Disease was $2.49 billion, up 8%; BioPharmaceuticals was $5.33 billion, down 7%; and China was $1.59 billion, down 13%[2]. Second-quarter core operating profit was $5.16 billion, up 10%, for a 34% margin, and core EPS was $2.63, up 18%, helped noticeably by a 15% tax rate; reported operating profit was $3.16 billion, down 13%[3], mainly because of a $345 million intangible impairment and higher amortization in the quarter[19].

First-half profit growth did not translate into cash, and borrowing rose on licensing deals and capital spending. First-half 2026 Total Revenue was $30.67 billion, up 6%[24], and core EPS was $5.21, up 11%[18]. Operating cash flow was $6.22 billion, $875 million lower than a year earlier, because working capital absorbed $1.44 billion and taxes paid rose by $502 million; investing outflows were $4.70 billion, including a $1.10 billion upfront payment to CSPC Pharmaceuticals[25]. Net debt was $26.91 billion at the end of June, up $3.54 billion from the start of the year[26]. The company then issued €2.55 billion of bonds in August[27] and on September 29 announced a $2 billion purchase of new Summit Therapeutics shares to co-develop ivonescimab, a PD-1/VEGF bispecific antibody[28].

Operating Model

AstraZeneca's revenue is set by treated patients, duration of therapy and net price; new indications add growth, while patent expiry and procurement subtract it. Product Sales equal patients treated times therapy duration times net price, where net price is list price after US commercial and Medicare rebates, European government pricing and Chinese reimbursement negotiations; Alliance Revenue is the portion partners pass back after booking sales. Growth comes mainly from new indications that widen the treatable population, such as Imfinzi in gastric and bladder cancer[29] and Enhertu in first-line HER2-positive breast cancer[30]; declines come mainly from patent expiry, such as the multiple US Farxiga generics that launched from the second quarter of 2026[7], and from Chinese VBP, which covered Farxiga, Lynparza and roxadustat from the first quarter of 2026[31]. Revenue is also seasonal: the US first quarter often carries inventory and gross-to-net adjustments, and Chinese ordering of Tagrisso follows a seasonal pattern; in the second quarter of 2026 Oncology was 48% of revenue, BioPharmaceuticals 35% and Rare Disease 16%[2]. On timing, a new indication ramps quarter by quarter as physicians adopt it and guidelines include it, while generic entry and VBP usually cut price and volume in the same quarter.

Core operating profit depends on a race between gross margin and launch spending. Core operating profit equals Total Revenue times core gross margin, minus core R&D and core SG&A, plus other operating income; core gross margin of about 83%-84% moves with the share of profit-sharing products, price cuts on medicines past exclusivity, pricing under the US government agreement and regional mix[19]. In the first half of 2026 core R&D was 23% of revenue and core SG&A was 26%, both rising with launch preparation and more Phase III trials; acquisition-related intangible amortization and impairment of $2.54 billion in the half hit only reported profit[18]. The core operating margin was about 31.5% in 2025[15] and rose to 34% in the second quarter of 2026, while the reported operating margin was only 21%[3]. Management guides only core EPS for the full year and has said the second-half gross margin will be lower than the first half because of seasonal lower-margin products, and that core finance costs will be higher than in the first half[9].

The cash model turns on whether operating cash flow can cover capital spending, licensing deals and dividends. Operating cash flow was $14.58 billion in 2025, and purchases of intangible assets, meaning licensing upfronts and milestones, were $3.10 billion, recorded in investing cash flow[20]. In the first half of 2026 operating cash flow was $875 million lower year on year because of working capital and taxes, while investing outflows rose with the CSPC upfront[25]. The second half still carries a $600 million upfront to Dizal and a $200 million upfront to Chia Tai Tianqing, a Sino Biopharmaceutical subsidiary[1], plus the $2 billion Summit equity investment[28], and management also looks for about $2.5 billion of milestone payments on earlier deals this year[9]. Layered on capital spending that is set to rise by about a third and a $3.30 per-share dividend, the direction of net debt depends on whether second-half operating cash flow recovers.

Industry and Competitive Position

AstraZeneca is one of the world's largest drugmakers by revenue and leads several niches, with 16 medicines that each generated more than $1 billion in 2025[32]. It leads in EGFR-mutated lung cancer (Tagrisso), BTK inhibitors for first-line chronic lymphocytic leukaemia (Calquence), HER2-targeted ADCs (Enhertu, with Daiichi Sankyo), complement C5 inhibitors (Ultomiris and Soliris) and SGLT2 inhibitors (Farxiga), while in PD-L1 immunotherapy it competes with Merck's Keytruda and Bristol Myers Squibb's Opdivo. In first-line lung cancer, its bispecific volrustomig plus chemotherapy was tested against Keytruda (pembrolizumab) plus chemotherapy, and that eVOLVE-Lung02 Phase III trial was discontinued in August[33].

Compared with most US and European peers, AstraZeneca stands out for its large China exposure and its growing reliance on molecules licensed from Chinese drugmakers. China was 12% of Product Sales in 2025[17], which exposes the company earlier and more directly to procurement price cuts and local innovative drugs, and management acknowledged on the second-quarter call that local competition is intensifying in EGFR and ADC indications[34]. At the same time, in 2026 it signed licensing deals with CSPC[25], Dizal and Sino Biopharmaceutical to replenish its pipeline[1], and it projects the US to be about half of Total Revenue by 2030[14]. Because the company does not report profit by therapy area and partners book the full market sales of Enhertu and Tezspire, whether these competitive strengths become a margin advantage can only be observed indirectly at group level.

Core Debates

Oncology still grew 15% in the second quarter. Can new indications for Imfinzi and Enhertu keep it growing above 13% in the third quarter while Tagrisso slows?

Oncology is AstraZeneca's main offset to declining older medicines, and whether it keeps growing at double digits directly determines the quality of full-year revenue guidance. Oncology was 48% of second-quarter revenue and grew 15% at CER[2], and management said first-half revenue grew 11% excluding Farxiga and Brilinta, with most of that underlying growth coming from Oncology[35]. If Oncology slips to single digits, the mid-to-high single-digit revenue guidance would lean more heavily on Rare Disease and Respiratory & Immunology.

Evidence for continued strong Oncology growth centres on new indications, while the drag centres on the largest product, Tagrisso, and on Lynparza. In the second quarter Imfinzi grew 27%, Enhertu 31%, Calquence posted $1.02 billion in quarterly revenue, up 16%, and newer drugs such as Truqap and Datroway grew quickly; at the same time Tagrisso grew only 6%, Lynparza fell 3% and Imjudo fell 7%[6]. The company attributed Imfinzi's growth to new gastric, bladder and lung cancer launches, while acknowledging a slowing and more competitive EGFR-mutated TKI market in China[29]; Tagrisso's second-quarter Emerging Markets revenue was $512 million, up only 1% at CER[8]. Enhertu's growth came from early adoption in first-line HER2-positive breast cancer[30], and on the first-quarter call management said underlying Tagrisso demand was still growing in the mid-teens[36].

Prescriptions for new indications reach Total Revenue through Oncology Product Sales and Alliance Revenue, but a rising share of profit-sharing products also lowers gross margin. Once a new indication is approved and enters guidelines, specialists prescribe Imfinzi, Enhertu and Calquence to new patients, lifting Oncology revenue; Enhertu, Datroway and Lynparza share profits with partners, so a larger share of them books more profit in cost of sales[19]. The unresolved question is how much of the fast growth in new indications reflects a low launch base: an alternative explanation holds that Imfinzi and Enhertu growth will fade quarter by quarter while the slowdown in Tagrisso, the largest product, weighs more on the total, pulling Oncology growth back to 10%-12%.

The third-quarter numbers that can test this debate directly are already clear. Watch whether Oncology revenue grows at least 13% at CER, whether Imfinzi growth stays above 22% with US growth still above 20%, whether Enhertu grows at least 25%, whether Tagrisso still grows around 5% and stabilizes in Emerging Markets, and what management says about Chinese competition for Tagrisso and Lynparza destocking. If Oncology growth falls below 12%, or Tagrisso turns to a year-on-year decline, the current reading that new indications are enough to carry growth would weaken.

In the first full quarter after US generics of Farxiga launched, how deep will the erosion be, and can the newer respiratory and immunology medicines make up for it?

Farxiga is still a large product for AstraZeneca, and the speed of its US erosion will set the pressure on the low end of full-year revenue guidance. Farxiga still generated $1.80 billion globally in the second quarter, down 19% at CER[37]; its US sales were $1.73 billion in 2025[38]. The company explicitly attributed the drop in first-half revenue growth from 11% to 6% to generics of Farxiga and Brilinta[35], so third-quarter US Farxiga revenue is the most direct variable for full-year guidance.

Current evidence shows erosion is already fast, but growth in newer respiratory and immunology medicines is also strong. US Farxiga fell from $449 million in the first quarter to $219 million in the second, and the company said multiple generics launched in the second quarter; Emerging Markets Farxiga fell 24% on Chinese VBP, while European Farxiga still grew 1% and has not yet lost exclusivity[8][7]. In the second quarter Cardiovascular, Renal & Metabolism revenue fell 18% overall and BioPharmaceuticals fell 7%, while Respiratory & Immunology grew 11%[2]; within it Tezspire grew 45%, Breztri 20% and Saphnelo 24%[37], and Fasenra grew 75% in Emerging Markets after its China NRDL listing, but Symbicort also faced a new generic competitor in the US[39].

Generic substitution and new-product uptake push BioPharmaceuticals revenue in opposite directions, and the net effect is still unsettled. US generic entry and Chinese VBP replace Farxiga prescriptions with low-priced generics and force the originator to cut price, lowering Cardiovascular, Renal & Metabolism revenue; meanwhile new patients and new indications for Tezspire, Fasenra, Breztri and Saphnelo lift Respiratory & Immunology, and the two together determine BioPharmaceuticals revenue. One explanation holds that the halving of second-quarter US revenue included channel destocking, so the third-quarter decline would narrow; conversely, if generic prices keep falling, US Farxiga could be left with only about $100 million in the third quarter.

In the third-quarter report, the test is whether the dollar level of US Farxiga and the growth rate of Respiratory & Immunology both hold up. Watch whether quarterly US Farxiga revenue falls below $110 million, whether global Farxiga revenue falls more than 25%, whether Respiratory & Immunology keeps growing above 10% with Tezspire at 35% or more, whether BioPharmaceuticals revenue falls more than 10%, and what management says about Farxiga's remaining exclusivity in Europe and US generic pricing. If US Farxiga revenue drops below $110 million, or Respiratory & Immunology growth falls below 8%, the view that newer products can absorb the erosion would weaken.

China revenue fell 13% in the second quarter. Has the hit from volume-based procurement bottomed out in the third quarter, or will local competition widen the decline?

China sets AstraZeneca apart from most US and European peers, and whether it stops declining will decide whether Emerging Markets, the second-largest region, can keep growing. China was 12% of the company's Product Sales in 2025[17]; from the first quarter of 2026 Farxiga and roxadustat entered VBP, and Lynparza was hit by generics and procurement[31], so China revenue at CER swung from 2% growth in the first quarter[40] to a 13% decline in the second[2].

Evidence that the decline has bottomed and evidence that it will worsen currently coexist. VBP took effect in the first quarter, making the second quarter the first full quarter after the shock; Fasenra grew 75% in Emerging Markets after its NRDL listing, Enhertu kept ramping after reimbursement[39], Emerging Markets excluding China grew 11%, and management said recent NRDL additions and 2026 approvals would drive future growth in China[35]. On the other side, Tagrisso grew only 1% in Emerging Markets in the second quarter and roxadustat fell 82%[8][37], and management acknowledged on the call that local competition is intensifying in EGFR and ADC indications[34].

VBP and reimbursement negotiations act on China revenue and group gross profit through both price and volume. VBP tender prices and NRDL prices set hospital volumes and unit prices, so procured products lose revenue sharply while newly reimbursed products gain volume; together they determine China revenue, which then feeds Emerging Markets revenue and group gross profit, with China carrying a lower gross margin than the US. An alternative explanation holds that part of the second-quarter 13% decline came from seasonal Tagrisso ordering in China and will recover in the third quarter, with the real VBP impact visible only on a full-year basis, so a single quarter may not show whether the decline has bottomed.

Whether the third-quarter report shows China bottoming depends mainly on two signals: the headline decline and Tagrisso. Watch whether the China revenue decline at CER narrows to within 8%, whether Tagrisso Emerging Markets revenue stops falling, whether Emerging Markets Farxiga falls more than 30%, the Emerging Markets growth of newly reimbursed products such as Fasenra, and whether management discloses new VBP products or local competitor launches. If the China decline exceeds 15%, or Tagrisso Emerging Markets falls more than 5% year on year, the view that the VBP hit has bottomed would be refuted.

With gross margin seasonally lower in the second half and launch spending rising, can the core operating margin hold around 33%, and does nine-month core EPS growth stay within the low double-digit guidance?

In a year when revenue grows only at a mid-to-high single-digit rate, AstraZeneca relies on margin expansion to deliver low double-digit core EPS growth. First-half revenue grew 6% at CER while core EPS grew 11%[4]; the third quarter is the key test of whether that leverage can last, because management has flagged a lower second-half gross margin and higher core finance costs[9].

Evidence that the margin can hold comes from costs growing more slowly than gross profit, while evidence against it comes from second-half seasonality and pricing pressure. The second-quarter core operating margin was 34%, 2 percentage points above a year earlier, with core gross margin at 84%, core R&D at 24% of revenue and core SG&A at 26%, and a 15% tax rate below the full-year 18%-22% range[3]. On the other hand, Farxiga generics and pricing changes under the US government agreement keep weighing on gross margin[19], several new drugs are in launch with sticky selling costs, and management listed new US most-favoured-nation (MFN) pricing rules as a risk that could lower net prices for new medicines[41].

Margin changes pass to core EPS through three layers: product mix, launch spending and tax. The share of profit-sharing products, generic price cuts and US agreement pricing set core gross margin; launches and Phase III trials set core SG&A and R&D, which together determine the core operating margin, and adding an 18%-22% core tax rate and higher second-half finance costs yields core EPS. An alternative explanation holds that part of the 18% second-quarter core EPS growth came from the low 15% tax rate and the timing of expenses, so third-quarter core EPS growth would return to single digits and nine-month growth would barely hold around 10%.

The third-quarter report needs to be read across margin, gross margin and expense ratios together. Watch whether the third-quarter core operating margin is at least 33%, whether nine-month core EPS growth at CER is at least 10%, whether core gross margin falls only seasonally to about 82%, whether core SG&A exceeds 27% of revenue, and whether management reaffirms full-year revenue and core EPS guidance. If the core operating margin falls below 31%, or nine-month core EPS growth drops below 9%, the view that margin leverage can continue would be refuted.

Risks and Falsifiers

Pipeline delivery risk surfaced in July through September 2026, when three important Phase III programmes failed or were stopped. Wainua's CARDIO-TTRansform missed its primary endpoint[42], volrustomig's eVOLVE-Lung02 was discontinued early[33], and Etcamah's first-line breast cancer trial SERENA-4 failed to show a statistically significant improvement in progression-free survival[43]; on the first-quarter call management had said camizestrant could become a $5 billion-plus product[44]. These failures do not affect third-quarter revenue from marketed medicines, but they erode the risk-adjusted assumptions behind the $80 billion 2030 ambition; management says 25 key Phase III readouts are due over the next 18 months[13], and failures could also bring intangible impairments charged to reported profit, after $345 million was booked in the second quarter[19]. If the third-quarter report reaffirms the 2030 ambition, new Phase III readouts are mostly positive and no large new impairment appears, this risk would be falsified for now.

Cash absorbed by licensing deals and capital spending could keep net debt rising in the second half. First-half operating cash flow fell $875 million year on year[25] and net debt rose to $26.91 billion[26]; the second half still includes upfronts of $600 million to Dizal and $200 million to Sino Biopharmaceutical[1] and the $2 billion Summit equity investment[28], about $2.8 billion combined, while full-year capital spending is planned to rise by about a third[21]. Adding the roughly $2.5 billion of milestone payments on earlier deals that management anticipates this year[9] and a $3.30 per-share dividend, cash outflows would outpace operating cash flow, and the company already issued €2.55 billion of bonds in August[27]. If the third-quarter report shows nine-month operating cash flow growing again year on year and net debt no longer rising meaningfully from the end of June, this risk would be falsified.

Tagrisso faces local EGFR-targeted competition and a slowing market in China, plus a new competitor in Japan, and as the largest product its slowdown dilutes gains from new indications. Based on second-quarter Tagrisso revenue of $1.94 billion, every 5-percentage-point drop in growth removes about $100 million of quarterly revenue, with the $512 million Emerging Markets portion most directly exposed[8][29]. If third-quarter Tagrisso growth at CER is at least 5% and Emerging Markets stops declining year on year, this risk would be falsified.

Generic erosion is happening in several regions at once: US Farxiga and Symbicort, Chinese VBP on Farxiga and generics in Japan's Farxiga diabetes indication, while Farxiga's exclusivity in Europe is also limited[7][39]. Farxiga generated $1.80 billion in the second quarter, of which the US and Emerging Markets together contributed $913 million[8][7]; if those two fell by another third, quarterly revenue would shrink by about $300 million, roughly 2 percentage points of Total Revenue. If third-quarter global Farxiga declines no more than 22% and US revenue stays at $150 million or more, this risk would be falsified.

Wider VBP coverage and local innovative competition could prolong the decline in China revenue. More originator drugs may enter VBP, and Chinese local products in EGFR and ADC indications are competing for share at lower prices[34]; China revenue was $1.59 billion in the second quarter[2], and on the 2025 base of $6.62 billion in China Product Sales[17], every 10% decline equals about $660 million of annual revenue, requiring faster growth in Emerging Markets outside China to keep the region growing overall. If the third-quarter China decline narrows to within 8% and Tagrisso Emerging Markets stops declining, this risk would be falsified.

US pricing policy could lower net prices for new medicines in the US, AstraZeneca's largest market. On the second-quarter call management said new MFN pricing rules require longer negotiation timelines and may lead to lower US net prices for new medicines than in the past, and the 2025 agreement with the US government has already brought pricing adjustments[41][19]; the US contributed $6.69 billion, or 43%, of second-quarter revenue[2], and the company projects it at about half by 2030[14], so pricing pressure falls directly on core gross margin and on the revenue slope of new medicines. If third-quarter core gross margin is at least 82% and US revenue growth at CER is at least the second quarter's 6%, this risk would be falsified.

What to Watch Next

• Oncology hand-off: Oncology revenue grew 15% at CER in the second quarter of 2026. Growth of at least 13% supports the hand-off; below 12% weakens it. Imfinzi (27%), Enhertu (31%) and Tagrisso (6%) should hold at or above 22%, 25% and about 5%; a Tagrisso decline weakens the case.
• Farxiga erosion and Respiratory & Immunology offset: US Farxiga was $219 million in the second quarter. A figure below $110 million means erosion is faster than the current baseline implies. Respiratory & Immunology (11%) and Tezspire (45%) should stay at or above 10% and 35%; Respiratory & Immunology below 8% means the offset falls short.
• China VBP and local competition: China revenue fell 13%. A decline narrowing to within 8% points to a bottom; a decline beyond 15% does not. Tagrisso Emerging Markets grew 1%; a drop of more than 5% signals sharper competition.
• Core margin and launch spending: core operating margin was 34% and core gross margin 84%. A margin of at least 33% with gross margin around 82% supports the leverage story; a margin below 31% breaks it. First-half core EPS grew 11%; nine-month growth below 9% would fall outside guidance.

Conclusion

AstraZeneca's growth is driven by new indications in Oncology, Rare Disease and Respiratory & Immunology, while its biggest drags are Farxiga's loss of exclusivity and Chinese procurement. Second-quarter Total Revenue was $15.38 billion, up 5%, with Oncology up 15%, BioPharmaceuticals down 7% and China down 13%[2]; the core operating margin was 34%[3] and first-half core EPS grew 11%[18], but operating cash flow fell year on year[25] and net debt rose to $26.91 billion[26]. The central unresolved relationship is whether gains from new medicines and indications can keep revenue growing at a mid-to-high single-digit rate while Tagrisso slows, US Farxiga revenue falls fast and Chinese procurement persists, and whether margin expansion can keep supporting low double-digit core EPS growth.

Outside commentary since the second-quarter results does not point the same way, but it centres on the Oncology hand-off debate. Zacks Investment Research wrote on September 28 that first-half Oncology revenue grew 15% at CER to $14.1 billion and argued that growth is shifting from a few established blockbusters such as Tagrisso toward newer drugs such as Truqap and Datroway and multiple new indications, with new indications and combinations offsetting the maturation of some older medicines[45]. STAT's Ed Silverman wrote on September 14 that the Etcamah (camizestrant) combination failed to beat standard treatment on progression-free survival in the first-line advanced breast cancer SERENA-4 Phase III trial, which could limit the drug's use, whereas a successful trial could have opened up a much larger market[46]. The two differ on how far new drugs can hedge the slowdown in older ones: Zacks emphasizes the breadth of new indications, while STAT signals that a single new-drug failure weakens that hedge, and management's earlier hope that camizestrant could exceed $5 billion now rests only on the approved ESR1-mutation population[44][43]. These are outside interpretations, not facts, and they do not amount to a majority view.

If the third-quarter report shows Oncology growth of at least 13%, US Farxiga revenue holding above $110 million with Respiratory & Immunology growing more than 10%, the China decline narrowing to within 8%, and a core operating margin of at least 33%, the current view that new medicines can offset erosion in older ones would strengthen materially. Conversely, if Oncology growth drops below 12%, Tagrisso turns negative, the China decline exceeds 15%, or the core operating margin falls below 31% with nine-month core EPS growth under 9%, that view would weaken; the direction of nine-month operating cash flow and net debt will show how much financial flexibility the company retains amid heavy licensing activity.

Sources

[1] AZN 6-K filed 2026-07-27 · business development and reporting calendar · 2026-07-27 · 6-K · https://www.sec.gov/Archives/edgar/data/901832/000110465926086846/azn-20260630x6k.htm

[2] AZN 6-K filed 2026-07-27 · Total Revenue by therapy area and region H1 and Q2 2026 · 2026-07-27 · 6-K · https://www.sec.gov/Archives/edgar/data/901832/000110465926086846/azn-20260630x6k.htm

[3] AZN 6-K filed 2026-07-27 · Q2 2026 key elements of financial performance · 2026-07-27 · 6-K · https://www.sec.gov/Archives/edgar/data/901832/000110465926086846/azn-20260630x6k.htm

[4] AZN 6-K filed 2026-07-27 · H1 2026 key performance and FY2026 guidance · 2026-07-27 · 6-K · https://www.sec.gov/Archives/edgar/data/901832/000110465926086846/azn-20260630x6k.htm

[5] Drillr analyst_financial_estimates (updated 2026-09-29) · AZN quarter ending 2026-09-30 · 2026-09-29 · Drillr analyst_financial_estimates · https://gateway.drillr.ai/mcp/private

[6] AZN 6-K filed 2026-07-27 · Oncology Product Revenue by medicine H1 and Q2 2026 · 2026-07-27 · 6-K · https://www.sec.gov/Archives/edgar/data/901832/000110465926086846/azn-20260630x6k.htm

[7] AZN 6-K filed 2026-07-27 · Farxiga and CVRM drivers H1 2026 · 2026-07-27 · 6-K · https://www.sec.gov/Archives/edgar/data/901832/000110465926086846/azn-20260630x6k.htm

[8] AZN 6-K filed 2026-07-27 · Q2 2026 Product Sales by region · 2026-07-27 · 6-K · https://www.sec.gov/Archives/edgar/data/901832/000110465926086846/azn-20260630x6k.htm

[9] AZN Q2 2026 earnings call 2026-07-27 · FY2026 guidance detail · 2026-07-27 · earnings-call · https://gateway.drillr.ai/mcp/private

[10] AZN 20-F filed 2026-02-24 · corporate history and NYSE direct listing · 2026-02-24 · 20-F · https://www.sec.gov/Archives/edgar/data/901832/000110465926019130/azn-20251231x20f.htm

[11] AZN 20-F filed 2026-02-24 · employees and R&D footprint · 2026-02-24 · 20-F · https://www.sec.gov/Archives/edgar/data/901832/000110465926019130/azn-20251231xex15d1.htm

[12] AZN 20-F filed 2026-02-24 · Ambition 2030 · 2026-02-24 · 20-F · https://www.sec.gov/Archives/edgar/data/901832/000110465926019130/azn-20251231xex15d1.htm

[13] AZN Q2 2026 earnings call 2026-07-27 · pipeline setbacks and 2030 ambition · 2026-07-27 · earnings-call · https://gateway.drillr.ai/mcp/private

[14] AZN 20-F filed 2026-02-24 · US agreement and US investment · 2026-02-24 · 20-F · https://www.sec.gov/Archives/edgar/data/901832/000110465926019130/azn-20251231xex15d1.htm

[15] AZN 20-F filed 2026-02-24 · FY2025 financial highlights · 2026-02-24 · 20-F · https://www.sec.gov/Archives/edgar/data/901832/000110465926019130/azn-20251231xex15d1.htm

[16] AZN 20-F filed 2026-02-24 · Total Revenue by therapy area and region FY2025 · 2026-02-24 · 20-F · https://www.sec.gov/Archives/edgar/data/901832/000110465926019130/azn-20251231xex15d1.htm

[17] AZN 20-F filed 2026-02-24 · Product Sales by region FY2025 and China · 2026-02-24 · 20-F · https://www.sec.gov/Archives/edgar/data/901832/000110465926019130/azn-20251231x20f.htm

[18] AZN 6-K filed 2026-07-27 · Reported to Core reconciliation H1 2026 · 2026-07-27 · 6-K · https://www.sec.gov/Archives/edgar/data/901832/000110465926086846/azn-20260630x6k.htm

[19] AZN 6-K filed 2026-07-27 · gross margin and cost drivers H1 2026 · 2026-07-27 · 6-K · https://www.sec.gov/Archives/edgar/data/901832/000110465926086846/azn-20260630x6k.htm

[20] AZN 20-F filed 2026-02-24 · cash flow and liquidity FY2025 · 2026-02-24 · 20-F · https://www.sec.gov/Archives/edgar/data/901832/000110465926019130/azn-20251231xex15d1.htm

[21] AZN 6-K filed 2026-07-27 · capital allocation and capex plan · 2026-07-27 · 6-K · https://www.sec.gov/Archives/edgar/data/901832/000110465926086846/azn-20260630x6k.htm

[22] AZN 6-K filed 2026-04-29 · Q1 2026 key performance and guidance · 2026-04-29 · 6-K · https://www.sec.gov/Archives/edgar/data/901832/000165495426004047/a2999c.htm

[23] AZN 6-K filed 2026-04-29 · Q1 2026 key elements of financial performance · 2026-04-29 · 6-K · https://www.sec.gov/Archives/edgar/data/901832/000165495426004047/a2999c.htm

[24] AZN 6-K filed 2026-07-27 · Reported Profit and Loss H1 and Q2 2026 · 2026-07-27 · 6-K · https://www.sec.gov/Archives/edgar/data/901832/000110465926086846/azn-20260630x6k.htm

[25] AZN 6-K filed 2026-07-27 · cash flow H1 2026 · 2026-07-27 · 6-K · https://www.sec.gov/Archives/edgar/data/901832/000110465926086846/azn-20260630x6k.htm

[26] AZN 6-K filed 2026-07-27 · net debt June 2026 · 2026-07-27 · 6-K · https://www.sec.gov/Archives/edgar/data/901832/000110465926086846/azn-20260630x6k.htm

[27] AZN 6-K filed 2026-08-25 · EUR2.55 billion bond offering · 2026-08-25 · 6-K · https://www.sec.gov/Archives/edgar/data/901832/000165495426007840/a9590r.htm

[28] AZN 6-K filed 2026-09-29 · equity investment in Summit Therapeutics · 2026-09-29 · 6-K · https://www.sec.gov/Archives/edgar/data/901832/000165495426008615/a6704w.htm

[29] AZN 6-K filed 2026-07-27 · Tagrisso Imfinzi Calquence drivers H1 2026 · 2026-07-27 · 6-K · https://www.sec.gov/Archives/edgar/data/901832/000110465926086846/azn-20260630x6k.htm

[30] AZN 6-K filed 2026-07-27 · Enhertu drivers H1 2026 · 2026-07-27 · 6-K · https://www.sec.gov/Archives/edgar/data/901832/000110465926086846/azn-20260630x6k.htm

[31] AZN 20-F filed 2026-02-24 · Emerging Markets Oncology and Lynparza VBP FY2025 · 2026-02-24 · 20-F · https://www.sec.gov/Archives/edgar/data/901832/000110465926019130/azn-20251231x20f.htm

[32] AZN 20-F filed 2026-02-24 · CEO review of 2025 therapy area performance · 2026-02-24 · 20-F · https://www.sec.gov/Archives/edgar/data/901832/000110465926019130/azn-20251231xex15d1.htm

[33] AZN 6-K filed 2026-08-17 · eVOLVE-Lung02 discontinuation · 2026-08-17 · 6-K · https://www.sec.gov/Archives/edgar/data/901832/000165495426007679/a8439q.htm

[34] AZN Q2 2026 earnings call 2026-07-27 · China competition Q&A · 2026-07-27 · earnings-call · https://gateway.drillr.ai/mcp/private

[35] AZN Q2 2026 earnings call 2026-07-27 · growth ex-Farxiga and China · 2026-07-27 · earnings-call · https://gateway.drillr.ai/mcp/private

[36] AZN Q1 2026 earnings call 2026-04-29 · Tagrisso demand and MFN Q&A · 2026-04-29 · earnings-call · https://gateway.drillr.ai/mcp/private

[37] AZN 6-K filed 2026-07-27 · BioPharmaceuticals and Rare Disease Product Revenue H1 and Q2 2026 · 2026-07-27 · 6-K · https://www.sec.gov/Archives/edgar/data/901832/000110465926086846/azn-20260630x6k.htm

[38] AZN 20-F filed 2026-02-24 · US Oncology and CVRM sales FY2025 · 2026-02-24 · 20-F · https://www.sec.gov/Archives/edgar/data/901832/000110465926019130/azn-20251231x20f.htm

[39] AZN 6-K filed 2026-07-27 · Respiratory and Immunology drivers H1 2026 · 2026-07-27 · 6-K · https://www.sec.gov/Archives/edgar/data/901832/000110465926086846/azn-20260630x6k.htm

[40] AZN 6-K filed 2026-04-29 · Q1 2026 Total Revenue by therapy area and region · 2026-04-29 · 6-K · https://www.sec.gov/Archives/edgar/data/901832/000165495426004047/a2999c.htm

[41] AZN Q2 2026 earnings call 2026-07-27 · stated risks · 2026-07-27 · earnings-call · https://gateway.drillr.ai/mcp/private

[42] AZN 6-K filed 2026-07-09 · CARDIO-TTRansform Phase III result · 2026-07-09 · 6-K · https://www.sec.gov/Archives/edgar/data/901832/000165495426006554/a6054l.htm

[43] AZN 6-K filed 2026-09-14 · SERENA-4 Phase III update · 2026-09-14 · 6-K · https://www.sec.gov/Archives/edgar/data/901832/000165495426008323/a5238u.htm

[44] AZN Q1 2026 earnings call 2026-04-29 · camizestrant commercial ambition · 2026-04-29 · earnings-call · https://gateway.drillr.ai/mcp/private

[45] Zacks 2026-09-28 · Is AstraZeneca's Oncology Portfolio Positioned for Continued Growth? · 2026-09-28 · Zacks Investment Research · https://www.zacks.com/stock/news/2996711/is-astrazeneca-s-oncology-portfolio-positioned-for-continued-growth

[46] STAT 2026-09-14 · Pharmalittle: another AstraZeneca trial failure · 2026-09-14 · STAT · https://www.statnews.com/pharmalot/2026/09/14/another-astrazeneca-trial-failure-novo-name-change/